Impact of fluorodeoxyglucose PET on the management of esophageal cancer. Nuclear Medicine Communications
dc.contributor.author | Salavati, A. | |
dc.contributor.author | Basu, Sandip | |
dc.contributor.author | Heidari, P. | |
dc.contributor.author | Alavi, A. | |
dc.date.accessioned | 2010-08-12T09:04:37Z | |
dc.date.available | 2010-08-12T09:04:37Z | |
dc.date.issued | 2009 | |
dc.format.extent | 4147 bytes | |
dc.format.mimetype | text/html | |
dc.identifier.uri | http://hdl.handle.net/123456789/3463 | |
dc.language.iso | en | en |
dc.subject | 18F-fluorodeoxyglucose | en |
dc.subject | esophageal neoplasms | en |
dc.subject | neoadjuvant therapy | en |
dc.subject | neoplasm staging | en |
dc.subject | positron emission tomography | en |
dc.subject | prognosis | en |
dc.title | Impact of fluorodeoxyglucose PET on the management of esophageal cancer. Nuclear Medicine Communications | en |
dc.type | Article | en |